Cargando…

Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark

Detalles Bibliográficos
Autores principales:	Aksan, Ayşegül, Dignass, Axel, Stein, Jürgen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822858/ https://www.ncbi.nlm.nih.gov/pubmed/31154627 http://dx.doi.org/10.1007/s12325-019-00990-x

Ejemplares similares

Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
por: Pollock, Richard F., et al.
Publicado: (2019)

Intravenous ferric carboxymaltose for the management of iron deficiency and iron deficiency anaemia in children and adolescents: a review
por: Aksan, Aysegül, et al.
Publicado: (2022)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia: Letter to Editor
por: Kanshaiym, Sakiyeva, et al.
Publicado: (2020)

Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and meta‐analysis
por: Schaefer, Benedikt, et al.
Publicado: (2020)

Differential Pharmacokinetics of Liver Tropism for Iron Sucrose, Ferric Carboxymaltose, and Iron Isomaltoside: A Clue to Their Safety for Dialysis Patients
por: Rostoker, Guy, et al.
Publicado: (2022)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia
por: Friedrisch, João Ricardo, et al.
Publicado: (2015)

Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia
por: Seid, Melvin H., et al.
Publicado: (2017)

Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease
por: Nordfjeld, Kim, et al.
Publicado: (2012)

Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy
por: Froessler, Bernd, et al.
Publicado: (2018)

Efficacy of ferric carboxymaltose in iron deficiency anemia patients scheduled for pancreaticoduodenectomy
por: Park, Jangho, et al.
Publicado: (2023)

Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy
por: Rognoni, Carla, et al.
Publicado: (2019)

Ferric carboxymaltose for treatment of iron deficiency and iron deficiency anemia caused by abnormal uterine bleeding
por: Hagras, Ahmed M., et al.
Publicado: (2022)

An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland
por: Pollock, Richard F, et al.
Publicado: (2021)

Management of iron deficiency anemia in inflammatory bowel disease – a practical approach
por: Stein, Jürgen, et al.
Publicado: (2013)

Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose
por: Toblli, Jorge Eduardo, et al.
Publicado: (2014)

Safety, pharmacokinetics, and pharmacodynamics of intravenous ferric carboxymaltose in children with iron deficiency anemia
por: Korczowski, Bartosz, et al.
Publicado: (2023)

Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017
por: Ehlken, Birgit, et al.
Publicado: (2018)

Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency Anemia
por: Hussain, Iftikhar, et al.
Publicado: (2013)

A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000
por: Pollock, Richard F, et al.
Publicado: (2017)

Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain
por: Argüelles-Arias, Federico, et al.
Publicado: (2022)

Comment on ‘Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron(III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ Between 2014 and 2017’
por: Schaffalitzky de Muckadell, Philip, et al.
Publicado: (2019)

Assessing the costs and benefits of perioperative iron deficiency anemia management with ferric carboxymaltose in Germany
por: Froessler, Bernd, et al.
Publicado: (2018)

Iron Deficiency Anemia with Menorrhagia: Ferric Carboxymaltose a Safer Alternative to Blood Transfusion
por: Mishra, Vineet, et al.
Publicado: (2018)

OR13-3 Effects of Iron Isomaltoside versus Ferric Carboxymaltose on Hormonal Control of Phosphate Homeostasis: The PHOSPHARE-IDA04/05 Randomized Controlled Trials
por: Wolf, Myles, et al.
Publicado: (2019)

Safety of intravenous iron isomaltoside for iron deficiency and iron deficiency anemia in pregnancy
por: Wesström, Jan
Publicado: (2020)

Comparison of ferric Carboxymaltose and iron sucrose complex for treatment of iron deficiency anemia in pregnancy- randomised controlled trial
por: Jose, Ambily, et al.
Publicado: (2019)

Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron
por: Lichtenstein, Gary R., et al.
Publicado: (2018)

Introducing iron isomaltoside 1000 (Monofer®)—development rationale and clinical experience
por: Kalra, Philip A.
Publicado: (2011)

MON-338 Severe Hypophosphatemia Induced by Intravenous Ferric Carboxymaltose Therapy for Iron Deficiency Anemia
por: Tam, Matthew, et al.
Publicado: (2020)

A prospective, multi‐center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON‐IDA trial
por: Auerbach, Michael, et al.
Publicado: (2019)

Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials
por: Naqash, Amreen, et al.
Publicado: (2018)

Intravenous Iron Isomaltoside 1000 Reduces Postoperative Anemia in Patients Undergoing Elective Urologic Surgery and Those with Urosepsis
por: Goh, Hyeok Jun, et al.
Publicado: (2020)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anaemia – reply
por: Cancado, Rodolfo Delfini, et al.
Publicado: (2020)

Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial
por: Bhandari, Sunil, et al.
Publicado: (2020)

Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemia
por: Kalra, Philip A, et al.
Publicado: (2016)

Iron isomaltoside is superior to iron sucrose in increasing hemoglobin in gynecological patients with iron deficiency anemia
por: Derman, Richard, et al.
Publicado: (2018)

A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia
por: Derman, Richard, et al.
Publicado: (2017)

Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial
por: Adkinson, N. Franklin, et al.
Publicado: (2018)

Successful Treatment of Iron Deficiency Anemia with Ferric Carboxymaltose in an Elderly Patient with Multiple Comorbidities and COVID-19
por: Bassi, Vincenzo, et al.
Publicado: (2021)

Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing
por: Diebold, Matthias, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4rvoik9dlv83np8n6oris7qjab